-
1
-
-
0029893146
-
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
-
DOI 10.1056/NEJM199605303342202
-
Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427. (Pubitemid 26157437)
-
(1996)
New England Journal of Medicine
, vol.334
, Issue.22
, pp. 1422-1427
-
-
Niederau, C.1
Heintges, T.2
Lange, S.3
Goldmann, G.4
Niederau, C.M.5
Mohr, L.6
Haussinger, D.7
-
2
-
-
0030730879
-
Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa
-
DOI 10.1053/gast.1997.v113.pm9352870
-
Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660-1667. (Pubitemid 27461254)
-
(1997)
Gastroenterology
, vol.113
, Issue.5
, pp. 1660-1667
-
-
Lau, D.T.-Y.1
Everhart, J.2
Kleiner, D.E.3
Park, Y.4
Vergalla, J.5
Schmid, P.6
Hoofnagle, J.H.7
-
3
-
-
0023762809
-
The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
-
Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-496.
-
(1988)
Hepatology
, vol.8
, pp. 493-496
-
-
Liaw, Y.F.1
Tai, D.I.2
Chu, C.M.3
-
4
-
-
0023771584
-
Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B
-
Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-1325.
-
(1988)
Gastroenterology
, vol.95
, pp. 1318-1325
-
-
Hoofnagle, J.H.1
Peters, M.2
Mullen, K.D.3
-
5
-
-
0024448926
-
Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? A statistical analysis of predictive factors
-
Brook MG, Karayiannis P, Thomas HC,. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-763. (Pubitemid 19270158)
-
(1989)
Hepatology
, vol.10
, Issue.5
, pp. 761-763
-
-
Brook, M.G.1
Karayiannis, P.2
Thomas, H.C.3
-
6
-
-
0025347975
-
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
-
Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295-301. (Pubitemid 20237094)
-
(1990)
New England Journal of Medicine
, vol.323
, Issue.5
, pp. 295-301
-
-
Perrillo, R.P.1
Schiff, E.R.2
Davis, G.L.3
Bodenheimer Jr., H.C.4
Lindsay, K.5
Payne, J.6
Dienstag, J.L.7
O'Brien, C.8
Tamburro, C.9
Jacobson, I.M.10
Sampliner, R.11
Feit, D.12
Lefkowitch, J.13
Kuhns, M.14
Meschievitz, C.15
Sanghvi, B.16
Albrecht, J.17
Gibas, A.18
Regenstein, F.G.19
-
7
-
-
0026602420
-
A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
-
Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-2097.
-
(1992)
Gastroenterology
, vol.102
, pp. 2091-2097
-
-
Lok, A.S.1
Wu, P.C.2
Lai, C.L.3
-
8
-
-
0036019518
-
Hepatitis B viral genotypes: Clinical relevance and molecular characteristics
-
Kao JH,. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643-650.
-
(2002)
J Gastroenterol Hepatol
, vol.17
, pp. 643-650
-
-
Kao, J.H.1
-
9
-
-
19944428132
-
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial
-
DOI 10.1016/S0140-6736(05)17701-0, PII S0140673605177010
-
Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129. (Pubitemid 40091801)
-
(2005)
Lancet
, vol.365
, Issue.9454
, pp. 123-129
-
-
Janssen, H.L.A.1
Van Zonneveld, M.2
Senturk, H.3
Zeuzem, S.4
Akarca, U.S.5
Cakaloglu, Y.6
Simon, C.7
So, T.M.K.8
Gerken, G.9
De Man, R.A.10
Niesters, H.G.M.11
Zondervan, P.12
Hansen, B.13
Schalm, S.W.14
-
10
-
-
0027378724
-
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis
-
Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J,. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323. (Pubitemid 23319890)
-
(1993)
Annals of Internal Medicine
, vol.119
, Issue.4
, pp. 312-323
-
-
Wong, D.K.H.1
Cheung, A.M.2
O'Rourke, K.3
Naylor, C.D.4
Detsky, A.S.5
Heathcote, J.6
-
11
-
-
40849105240
-
Hepatitis B: Reflections on the current approach to antiviral therapy
-
Zoulim F, Perrillo R,. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48: S2-S19.
-
(2008)
J Hepatol
, vol.48
-
-
Zoulim, F.1
Perrillo, R.2
-
12
-
-
70649104668
-
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa
-
Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-2009.
-
(2009)
Gastroenterology
, vol.137
, pp. 2002-2009
-
-
Buster, E.H.1
Hansen, B.E.2
Lau, G.K.3
-
13
-
-
0029806124
-
Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B
-
Hayashi PH, Beames MP, Kuhns MC, Hoofnagle JH, Di Bisceglie AM,. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B. Am J Gastroenterol 1996; 91: 2323-2328. (Pubitemid 26383194)
-
(1996)
American Journal of Gastroenterology
, vol.91
, Issue.11
, pp. 2323-2328
-
-
Hayashi, P.H.1
Beames, M.P.2
Kuhns, M.C.3
Hoofnagle, J.H.4
Di Bisceglie, A.M.5
-
14
-
-
0031183753
-
Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV DNA in monitoring the response to treatment in patients with chronic hepatitis B
-
Bernard F, Raymond G, Willems B, Villeneuve JP,. Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV-DNA in monitoring the response to treatment in patients with chronic hepatitis B. J Viral Hepat 1997; 4: 265-272. (Pubitemid 127733433)
-
(1997)
Journal of Viral Hepatitis
, vol.4
, Issue.4
, pp. 265-272
-
-
Bernard, E.1
Raymond, G.2
Willems, B.3
Villeneuve, J.-P.4
-
15
-
-
0033816667
-
Interferon-alpha therapy in chronic hepatitis B: Early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy
-
Heijtink RA, Janssen HL, Hop WC, Osterhaus AD, Schalm SW,. Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J Viral Hepat 2000; 7: 382-386.
-
(2000)
J Viral Hepat
, vol.7
, pp. 382-386
-
-
Heijtink, R.A.1
Janssen, H.L.2
Hop, W.C.3
Osterhaus, A.D.4
Schalm, S.W.5
-
16
-
-
14844325741
-
Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B
-
DOI 10.1111/j.1365-2893.2005.00602.x
-
Park NH, Shin JW, Park JH, et al. Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B. J Viral Hepat 2005; 12: 216-221. (Pubitemid 40342182)
-
(2005)
Journal of Viral Hepatitis
, vol.12
, Issue.2
, pp. 216-221
-
-
Park, N.H.1
Shin, J.W.2
Park, J.H.3
Bang, S.-J.4
Kim, D.-H.5
Joo, K.R.6
Kim, D.H.7
-
17
-
-
0035172849
-
Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers
-
DOI 10.1128/JCM.39.1.362-364.2001
-
Natio H, Hayashi S, Abe K,. Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. J Clin Microbiol 2001; 39: 362-364. (Pubitemid 32059621)
-
(2001)
Journal of Clinical Microbiology
, vol.39
, Issue.1
, pp. 362-364
-
-
Naito, H.1
Hayashi, S.2
Abe, K.3
-
18
-
-
18944387675
-
YMDD variants to HBV DNA polymerase gene: Rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation
-
Pei F, Ning JY, You JF, Yang JP, Zheng J,. YMDD variants of HBV DNA polymerase gene: rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation. World J Gastroenterol 2005; 11: 2714-2719. (Pubitemid 40704235)
-
(2005)
World Journal of Gastroenterology
, vol.11
, Issue.18
, pp. 2714-2719
-
-
Pei, F.1
Ning, J.-Y.2
You, J.-F.3
Yang, J.-P.4
Zheng, J.5
-
19
-
-
28244469080
-
Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B
-
Sertoz RY, Erensoy S, Pas S, et al. Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B. J Chemother 2005; 17: 514-520. (Pubitemid 41699715)
-
(2005)
Journal of Chemotherapy
, vol.17
, Issue.5
, pp. 514-520
-
-
Sertoz, R.Y.1
Erensoy, S.2
Pas, S.3
Akarca, U.S.4
Ozgenc, F.5
Yamazhan, T.6
Ozacar, T.7
Niesters, H.G.M.8
-
20
-
-
0015433262
-
New specificities in Australia antigen positive sera distinct from the le Bouvier determinants
-
Magnius LO, Espmark JA,. New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants. J Immunol 1972; 109: 1017-1021.
-
(1972)
J Immunol
, vol.109
, pp. 1017-1021
-
-
Magnius, L.O.1
Espmark, J.A.2
-
21
-
-
0017761044
-
Hepatitis B e antigen and infectivity of hepatitis B virus
-
Shikata T, Karasawa T, Abe K, et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis 1977; 136: 571-576. (Pubitemid 8211390)
-
(1977)
Journal of Infectious Diseases
, vol.136
, Issue.4
, pp. 571-576
-
-
Shikata, T.1
Karasawa, T.2
Abe, K.3
-
22
-
-
0026683254
-
Correlation between the prevalence of serum HBV DNA and immunoserologic HBV markers in the subjects with or without hepatitis
-
Luo KX, Zhou R, Liang ZS, Jiang S,. Correlation between the prevalence of serum HBV DNA and immunoserologic HBV markers in the subjects with or without hepatitis. Immunol Invest 1992; 21: 275-281.
-
(1992)
Immunol Invest
, vol.21
, pp. 275-281
-
-
Luo, K.X.1
Zhou, R.2
Liang, Z.S.3
Jiang, S.4
-
23
-
-
8644265121
-
Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C
-
DOI 10.1128/JCM.42.11.5036-5040.2004
-
Yuen MF, Fung SK, Tanaka Y, et al. Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C. J Clin Microbiol 2004; 42: 5036-5040. (Pubitemid 39506207)
-
(2004)
Journal of Clinical Microbiology
, vol.42
, Issue.11
, pp. 5036-5040
-
-
Yuen, M.-F.1
Fung, S.K.2
Tanaka, Y.3
Kato, T.4
Mizokami, M.5
Yuen, J.C.-H.6
Wong, D.K.-H.7
Yuan, H.-J.8
Sum, S.-M.9
Chan, A.O.-O.10
Wong, B.C.-Y.11
Lai, C.-L.12
-
24
-
-
33744753396
-
Chronic hepatitis B: Current testing strategies
-
DOI 10.1016/j.cgh.2006.03.017, PII S1542356506002692
-
Gish RG, Locarnini SA,. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 2006; 4: 666-676. (Pubitemid 43825809)
-
(2006)
Clinical Gastroenterology and Hepatology
, vol.4
, Issue.6
, pp. 666-676
-
-
Gish, R.G.1
Locarnini, S.A.2
-
25
-
-
70350133508
-
Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naîve patients
-
Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naîve patients. J Hepatol 2009; 50 (Suppl): S10.
-
(2009)
J Hepatol
, vol.50
, Issue.SUPPL.
-
-
Tenney, D.J.1
Pokornowski, K.A.2
Rose, R.E.3
-
26
-
-
35649020315
-
Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B
-
DOI 10.1053/j.gastro.2007.08.025, PII S0016508507014825
-
Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444. (Pubitemid 350029745)
-
(2007)
Gastroenterology
, vol.133
, Issue.5
, pp. 1437-1444
-
-
Gish, R.G.1
Lok, A.S.2
Chang, T.3
De Man, R.A.4
Gadano, A.5
Sollano, J.6
Han, K.7
Chao, Y.8
Lee, S.9
Harris, M.10
Yang, J.11
Colonno, R.12
Brett-Smith, H.13
-
27
-
-
84855801543
-
Five years of continuous entecavir for nucleoside-naîve HBeAg(+) chronic hepatitis B: Results from study ETV-901
-
Abstract No.: OP-48, Mar 20-24; Washington, DC. Available at: (accessed 2 June 2009)
-
Han SH, Chang TT, Chao YC, et al. Five years of continuous entecavir for nucleoside-naîve HBeAg(+) chronic hepatitis B: results from study ETV-901. Abstract No.: OP-48. Proceedings of the 13th International Symposium on Viral Hepatitis and Liver Disease; 2009 Mar 20-24; Washington, DC. Available at: (accessed 2 June 2009).
-
(2009)
Proceedings of the 13th International Symposium on Viral Hepatitis and Liver Disease
-
-
Han, S.H.1
Chang, T.T.2
Chao, Y.C.3
-
28
-
-
79959590320
-
-
Bristol Myers-Squibb Available at: (accessed 1 June 2009)
-
Bristol Myers-Squibb. Entecavir AVDAC briefing document; 2005. Available at: (accessed 1 June 2009).
-
(2005)
Entecavir AVDAC Briefing Document
-
-
-
29
-
-
77955981141
-
Entecavir induced HBV DNA suppression at 12 weeks in treatment-naive patients with chronic hepatitis B is a good predictive factor for virological response at 48 weeks
-
Lee HW, Kim HJ, Kim MH, et al. Entecavir induced HBV DNA suppression at 12 weeks in treatment-naive patients with chronic hepatitis B is a good predictive factor for virological response at 48 weeks. Hepatology 2008; 48: 741A.
-
(2008)
Hepatology
, vol.48
-
-
Lee, H.W.1
Kim, H.J.2
Kim, M.H.3
-
30
-
-
65849220728
-
Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48
-
Ma H, Ren JB, Li HY, et al. Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2007; 21: 102-104.
-
(2007)
Zhonghua Shi Yan He Lin Chuang Bing du Xue Za Zhi
, vol.21
, pp. 102-104
-
-
Ma, H.1
Ren, J.B.2
Li, H.Y.3
-
31
-
-
34248682646
-
Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study
-
DOI 10.1128/JCM.00732-06
-
Laperche S, Thibault V, Bouchardeau F, et al. Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study. J Clin Microbiol 2006; 44: 3600-3607. (Pubitemid 46768819)
-
(2006)
Journal of Clinical Microbiology
, vol.44
, Issue.10
, pp. 3600-3607
-
-
Laperche, S.1
Thibault, V.2
Bouchardeau, F.3
Alain, S.4
Castelain, S.5
Gassin, M.6
Gueudin, M.7
Halfon, P.8
Larrat, S.9
Lunel, F.10
Martinot-Peignoux, M.11
Mercier, B.12
Pawlotsky, J.-M.13
Pozzetto, B.14
Roque-Afonso, A.-M.15
Roudot-Thoraval, F.16
Saune, K.17
Lefrere, J.-J.18
-
32
-
-
0033983436
-
Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: Performance of three commercial assays
-
DOI 10.1016/S0166-0934(99)00149-4, PII S0166093499001494
-
Pawlotsky JM, Bastie A, Hezode C, et al. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays. J Virol Methods 2000; 85: 11-21. (Pubitemid 30068578)
-
(2000)
Journal of Virological Methods
, vol.85
, Issue.1-2
, pp. 11-21
-
-
Pawlotsky, J.-M.1
Bastie, A.2
Hezode, C.3
Lonjon, I.4
Darthuy, F.5
Remire, J.6
Dhumeaux, D.7
-
33
-
-
0036094158
-
Molecular diagnosis of viral hepatitis
-
Pawlotsky JM,. Molecular diagnosis of viral hepatitis. Gastroenterology 2002; 122: 1554-1568.
-
(2002)
Gastroenterology
, vol.122
, pp. 1554-1568
-
-
Pawlotsky, J.M.1
-
34
-
-
0027486290
-
Monitoring of antiviral therapy with quantitative evaluation of HBeAg: A comparison with HBV DNA testing
-
DOI 10.1016/0270-9139(93)90216-A
-
Perrillo R, Mimms L, Schechtman K, Robbins D, Campbell C,. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. Hepatology 1993; 18: 1306-1312. (Pubitemid 23348414)
-
(1993)
Hepatology
, vol.18
, Issue.6
, pp. 1306-1312
-
-
Perrillo, R.1
Mimms, L.2
Schechtman, K.3
Robbins, D.4
Campbell, C.5
-
35
-
-
0031419744
-
Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B
-
DOI 10.1002/(SICI)1096-9071(199711)53:3<282::AID-JMV18>3.0.CO;2-J
-
Heijtink RA, Kruining J, Honkoop P, et al. Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B. J Med Virol 1997; 53: 282-287. (Pubitemid 28201840)
-
(1997)
Journal of Medical Virology
, vol.53
, Issue.3
, pp. 282-287
-
-
Heijtink, R.A.1
Kruining, J.2
Honkoop, P.3
Kuhns, M.C.4
Hop, W.C.J.5
Osterhaus, A.D.M.E.6
Schalm, S.W.7
-
36
-
-
39549114267
-
HBeAg and hepatitis B Virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
-
DOI 10.1002/hep.22065
-
Fried MW, Piratvisuth T, Lau GKK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428-434. (Pubitemid 351280710)
-
(2008)
Hepatology
, vol.47
, Issue.2
, pp. 428-434
-
-
Fried, M.W.1
Piratvisuth, T.2
Lau, G.K.K.3
Marcellin, P.4
Chow, W.-C.5
Cooksley, G.6
Luo, K.-X.7
Paik, S.W.8
Liaw, Y.-F.9
Button, P.10
Popescu, M.11
-
37
-
-
33748305988
-
Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays
-
DOI 10.1016/j.antiviral.2006.05.006, PII S016635420600132X
-
Zhou T, Guo H, Guo J-T, Cuconati A, Mehta A, Block TM,. Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res 2006; 72: 116-124. (Pubitemid 44332566)
-
(2006)
Antiviral Research
, vol.72
, Issue.2
, pp. 116-124
-
-
Zhou, T.1
Guo, H.2
Guo, J.-T.3
Cuconati, A.4
Mehta, A.5
Block, T.M.6
-
38
-
-
70449673114
-
Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B
-
da Silva LC, Nova ML, Ono-Nita SK, et al. Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B. Rev Inst Med Trop Sao Paulo 2009; 51: 261-268.
-
(2009)
Rev Inst Med Trop Sao Paulo
, vol.51
, pp. 261-268
-
-
Da Silva, L.C.1
Nova, M.L.2
Ono-Nita, S.K.3
-
39
-
-
75449107726
-
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
-
Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430.
-
(2010)
Hepatology
, vol.51
, pp. 422-430
-
-
Chang, T.T.1
Lai, C.L.2
Kew Yoon, S.3
|